The challenge for allogeneic hematopoietic stem cell transplantation in acute leukemia/ myelodyplastic syndrom with TP53, TET2 or DNMT3A gene mutations

VernacularTitle:异基因造血干细胞移植治疗携带TP53、TET2、DNMT3A 基因突变的急性白血病/MDS的挑战
Author: Rui ZHANG ¹ ; Dai-hong LIU ²
Author Information

1. Department of Hematology, Cangzhou Central Hospital, Hebei 061001, China
2. Department of Hematology, Chinese PLA General Hospital
Publication Type:Journal Article
Keywords: hematopoietic stem cell transplantation; leukemia, myeloid, acute; leukemia, lymphoid; myelodysplastic syndromes; gene, p53; DNMT3A; TET2
From: Tianjin Medical Journal 2018;46(8):837-841
CountryChina
Language:Chinese
Abstract: Recently, much gene mutations have been detected in patients with acute leukemia or myelodysplastic syndrome (MDS) using next-generation sequencing (NSG) technology. Some of them are proved to be important prognostic markers. It has been showed that TP53, TET2 or DNMT3A gene mutations are associated with poor prognosis in acute leukemia or MDS patients. The prognosis of these patients is poor with short remission and survival. Allogeneic hematopoietic stem cell transplantation is the only way to cure these patients. However, the outcomes after transplantation are inferior to those in patients without these mutations. The hypomethylating agents or immune targeting therapy might improve their prognosis when combined with the present strategies. Here, the impact of TP53, TET2 and DNMT3A gene mutations on the prognosis after chemotherapy or transplantation is reviewed.